| Users rating | no rating |
Candioli - Confis Start - 40 Tablets
Brand: Confis
Producer: Candioli
Confis Ultra is a dietary complementary feed intended for particular nutritional purposes, designed to support joint metabolism in cases of osteoarthritis.
It uses exclusive ingredients (Glucosamine, Chondroitin sulphate, Flexide, Low molecular weight hyaluronic acid and the native Collagen type II) specially formulated in tablets for administration to the dog in case of osteoarthritis.
Composition:
Glucosamine (Chitosamine) (from animal tissues), Fatty acid salts from Flax oil (α-linolenic acid), Chondroitin sulfate, Pork by-products, Dicalcium phosphate, Sugar, Yeasts [Brewer's yeast], Plant-based by-products, Fish oil, Magnesium stearate.
ADDITIVES PER KG Stabilizers: Microcrystalline cellulose E460 mg 119,500. Anti-caking agents: Colloidal silica E551b mg 70,300. Vitamins: Vitamin E 3a700 IU 6,250. Trace elements 3b503 Manganous sulphate, monohydrate - manganese mg 1040.
ANALYTICAL COMPONENTS Crude protein 12.0%- Crude fibres 17.0% - Crude fats 15.0% - Crude ash 18.0% - Moisture 5.0% - Omega-3 fatty acids 3.4% - Eicosapentaenoic acid 0.40% - Vitamin E 0.62%.
Correct use:
CONFIS Start is a dietary complementary feed for adult dogs and puppies, formulated to support joint metabolism in osteoarthritis.Administer CONFIS Start directly into the mouth or mix into the usual food ration according to the following quantities:
- 0-10 kg pv 1/2 tablet
- 10-20 kg pv 1 tablet
- 20-30 kg pv1+1/2 tablet
- 30-40kg pv 2 tablets
- >40 kg pv 2+1/2
tabletsRecommended period of employment: up to three months initially. It is recommended to seek veterinary advice before use or before extending the period of use.It is recommended to carry out administration cycles every 3/6 months for at least 6/8 weeks, according to the dog's weight, to obtain the expected benefit on joint metabolism. The tablets can be administered in a single daily amount.
In each tablet:
Glucosamine (Chitosamine) from animal tissues: 500mg
Chondroitin sulfate: 400mg
Osteoarthritis:
Osteoarthritis (OA) is the most common arthropathy in mammals, including cats, and is estimated to affect over 20% of all dogs over 1 year of age; it is the leading cause of pain and lameness in dogs.Although found in animals of any age, its incidence increases with the age of the dog, particularly with age. Approximately 45% of large dogs suffer from OA, and some breeds, such as the German Shepherd and Labrador Retriever, appear genetically predisposed to developing this condition. Furthermore, large or giant breed dogs have a high incidence of orthopedic growth disorders that can lead to OA in more advanced stages.OA is a degenerative disease characterized by chronic pain, the mechanism by which it occurs is not yet fully understood, although it is thought to result from the stimulation of nociceptors present at the level of the synovial membrane, joint capsule, intra- and periarticular ligaments, and subchondral bone (Macias Ldo 2010). Nociceptors are activated by proinflammatory mediators such as prostaglandins, leukotrienes, and free radicals (nitric oxide).
Product images are purely indicative and may therefore not be perfectly representative of the packaging, product characteristics, differing in colours, dimensions or content. Any decorations, gift boxes and items included in the images for the purpose of product presentation will not be shipped in orders. The product names, ingredients and percentages given in the descriptions are indicative only, they may be changed or updated by the manufacturing companies. Due to the inability to comply with these updates in real time, the photos and technical information of the products listed on www.88alimentiperanimali.it may differ from those listed on the label or otherwise distributed by the manufacturers. www.88alimentiperanimali.it does not guarantee the veracity and timeliness of the published information and disclaims any responsibility for any errors, omissions, or failure to update it. www.88alimentiperanimali.it assumes no responsibility for any damages that may arise from access to published information.
